

Curriculum Vitae
Deborah Gardner Nixon, MD

Practice Address: Dermatology Specialists of Charlotte
8936 Blakeney Professional Drive
Charlotte, NC 28277
Deborah.nixon@dscmd.com

Site Affiliation: DJL Clinical Research, PLLC
2017-Present 10370 Park Road, Suite 200
Charlotte, NC 28210

Education:

1995-1998	Residency in Dermatology
1997-1998	Chief Administrative Resident University of South Florida Medical Center Tampa, Florida
1993-1995	Residency in Internal Medicine Georgetown University Medical Center Washington, DC
1992-1993	Internship in Internal Medicine Vanderbilt University Medical Center Nashville, Tennessee
1988-1992	Doctor of Medicine University of North Carolina at Chapel Hill School of Medicine Chapel Hill, North Carolina
1984-1988	Bachelor of Science in Zoology Duke University Durham, North Carolina

Professional Experience:

2006-Present	Dermatologist/Owner Dermatology Specialists of Charlotte
2000-2006	Dermatologist Carolina Dermatology
1998-2000	Dermatologist The Dermatology Group, PA

Licensure/Certifications:

- 1998-Present Dermatology Board Certified – State of North Carolina
- 1995-2005 Internal Medicine Board Certified– State of North Carolina

Curriculum Vitae
Deborah Gardner Nixon, MD

Professional Memberships:

1995-Present	Fellow of the American Academy of Dermatology
2003-Present	Fellow of the American Society of Dermatologic Surgeons
1998-Present	North Carolina Dermatology Association
1999-Present	Mecklenburg County Medical Society

Clinical Research:

Sub-Investigator – Abbvie: A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) –SELECT – PsA 2 (2017)

Principal Investigator – Cutanea Life Sciences, Inc: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 in Subjects 2 years of age or older with Cutaneous Common Warts (2017)


Principal Investigator – Vanda: A Randomized, Double-Blind, Placebo Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis. 2019

Principal Investigator – Chemocentryx: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. 2019

Principal Investigator – Skintech: A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris. 2019

Principal Investigator – Eli Lilly: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata. BRAVE-AA2. 2019

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.



Signature

26 Feb 2020

Date